(Q39441327)

12 September 2017

title

Targeting TGF-β Signaling in Cancer (English)

1 reference

12 September 2017

2

Peter Ten Dijke

1 reference

12 September 2017

Selcuk Colak

1

1 reference

12 September 2017

publication date

3 January 2017

1 reference

12 September 2017

1 reference

12 September 2017

volume

3

1 reference

12 September 2017

issue

1

1 reference

12 September 2017

page(s)

56-71

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

12 September 2017

1 reference

The consensus molecular subtypes of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGF-β signalling and its role in cancer progression and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Targeting the TGFβ signalling pathway in disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Role of Smads in TGFβ signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Non-Smad signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGFβ signalling in context

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Matters of context guide future research in TGFβ superfamily signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Active CREB1 promotes a malignant TGFβ2 autocrine loop in glioblastoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Beyond TGFβ: roles of other TGFβ superfamily members in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Molecular genetics of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Transforming Growth Factor β Signaling in Colorectal Cancer Cells With Microsatellite Instability Despite Biallelic Mutations in TGFBR2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Smad2 and Smad4 gene mutations in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGF-β Tumor Suppression through a Lethal EMT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Mechanisms of TGFβ-Induced Epithelial-Mesenchymal Transition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Immunoregulation by members of the TGFβ superfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

The polarization of immune cells in the tumour environment by TGFbeta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Smad4 signalling in T cells is required for suppression of gastrointestinal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Mutations in the SMAD4/DPC4 gene in juvenile polyposis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Genetic risks and familial associations of small bowel carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Signaling by members of the TGF-beta family in vascular morphogenesis and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Endoglin for tumor imaging and targeted cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Interactions between cancer stem cells and their niche govern metastatic colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Myofibroblasts differentiate from fibroblasts when plated at low density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Stromal myofibroblasts are drivers of invasive cancer growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Mesenchymal Stem Cells are Recruited and Activated into Carcinoma-Associated Fibroblasts by Prostate Cancer Microenvironment-Derived TGF-β1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Discovery of Endothelial to Mesenchymal Transition as a Source for Carcinoma-Associated Fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

IKKβ acts as a tumor suppressor in cancer-associated fibroblasts during intestinal tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

IKKβ in intestinal mesenchymal cells promotes initiation of colitis-associated cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Induction of heart valve lesions by small-molecule ALK5 inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

An integrated genomic analysis of human glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGF-β: an emerging player in drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Cancer stem cells--important players in tumor therapy resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

The epithelial-mesenchymal transition generates cells with properties of stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Plasma levels of transforming growth factor-beta 1 before and after removal of low- and high-grade astrocytomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Targeting the Microenvironment in Advanced Colorectal Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

The prognostic role of TGF-β signaling pathway in breast cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Considerations in the development of circulating tumor cell technology for clinical use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Liquid biopsies: genotyping circulating tumor DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Circulating tumor cells predict survival in early average-to-high risk breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Cell-free nucleic acids as biomarkers in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.11.008

10.1016/J.TRECAN.2016.11.008

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference